Clinical Trial Update: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 randomized trial at University College London compares Rituxan (rituximab) plus Ibrutinib versus Dexamethasone, Rituxan, and Cyclophosphamide …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Cytoxan (cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: University College, London | Conditions: Waldenstrom Macroglobulinemia | Phase 2, Phase 3 | Status: RECRUITING